ADXS31142 Immunotherapy ± PembrolizumabTreatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

Stein, M. N., Fong, L., Tutrone, R., Mega, A., Lam, E. T., Parsi, M., Vangala, S., Gutierrez, A. A., & Haas, N. B. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist, 27(6), 453–461. https://doi.org/10.1093/oncolo/oyac048
Authors:
Mark N. Stein
Lawrence Fong
Ronald Tutrone
Anthony Mega
Elaine T. Lam
Megan Parsi
Surya Vangala
Andres A. Gutierrez
Naomi B. Haas
Affiliated Authors:
Mark N. Stein
Columbia Affiliation:
Subjects:
Advancements in Prostate Cancer Research (OpenAlex Topic)
Cancer Immunotherapy (OpenAlex Topic)
Immunobiology of Dendritic Cells (OpenAlex Topic)
Prostatic Neoplasms, Castration-Resistant (MeSH)
Author Keywords:
immunotherapy
metastatic castration-resistant prostate cancer (mcrpc)
lm vectors
pembrolizumab
prostate-specific antigen (psa)
elink
Publication Type:
Article
Unique ID:
10.1093/oncolo/oyac048
PMID:
35373299
DOI:
10.1093/oncolo/oyac048
Journal:
Oncologist
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View PubMed Record
View Web of Science Record
View OpenAlex Record

Record Created: